Author: Laura Riva; Shuofeng Yuan; Xin Yin; Laura Martin-Sancho; Naoko Matsunaga; Sebastian Burgstaller-Muehlbacher; Lars Pache; Paul P. De Jesus; Mitchell V. Hull; Max Chang; Jasper Fuk-Woo Chan; Jianli Cao; Vincent Kwok-Man Poon; Kristina Herbert; Tu-Trinh Nguyen; Yuan Pu; Courtney Nguyen; Andrey Rubanov; Luis Martinez-Sobrido; Wen-Chun Liu; Lisa Miorin; Kris M. White; Jeffrey R. Johnson; Christopher Benner; Ren Sun; Peter G. Schultz; Andrew Su; Adolfo Garcia-Sastre; Arnab K. Chatterjee; Kwok-Yung Yuen; Sumit K. Chanda
Title: A Large-scale Drug Repositioning Survey for SARS-CoV-2 Antivirals Document date: 2020_4_17
ID: 1fgnfh62_34
Snippet: Although both the entry receptor for SARS-CoV-2, ACE2, and the priming protease TMPRSS2, were found to be expressed within specific anatomical sampling locations in the respiratory tract ( Figure 2B, left heatmap) , ACE2 expression was found to be restricted to epithelial cell types including multiciliated, nasal, deuterosomal, secretory, and basal cells ( Figure 2B, right heatmap) . Nonetheless, ACE2 expression has been reported to be induced by.....
Document: Although both the entry receptor for SARS-CoV-2, ACE2, and the priming protease TMPRSS2, were found to be expressed within specific anatomical sampling locations in the respiratory tract ( Figure 2B, left heatmap) , ACE2 expression was found to be restricted to epithelial cell types including multiciliated, nasal, deuterosomal, secretory, and basal cells ( Figure 2B, right heatmap) . Nonetheless, ACE2 expression has been reported to be induced by type-I interferon 90 . Notably, a majority of the mapped targets of active compounds also harbored expression in relevant respiratory epithelial cells, suggesting these may be physiologically relevant drug targets ( Figure 2B) . Further pathway analyses of these enriched MOAs and targets revealed enrichment in genes involved in nuclear receptor pathways, GPCR ligand binding and signaling, and calcium signaling ( Figure S3) , underscoring the potential critical role of these molecular circuits in cellular control of the SARS-CoV-2 life cycle 40 .
Search related documents:
Co phrase search for related documents- active compound and critical role: 1
- active compound and drug target: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
- active compound and entry receptor: 1
- active compound and epithelial cell: 1, 2
- active compound and pathway analysis: 1, 2
- active compound and respiratory tract: 1, 2, 3
- active compound and SARS life: 1, 2, 3
- active compound and SARS life cycle: 1, 2, 3
- basal secretory and cell type: 1, 2, 3, 4
- basal secretory and epithelial cell: 1, 2, 3
- basal secretory and respiratory tract: 1, 2
- basal secretory and type induce: 1
- cell type and critical role: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24
- cell type and drug target: 1, 2, 3, 4, 5, 6, 7, 8, 9
- cell type and entry receptor: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28
- cell type and epithelial cell: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74
- cell type and pathway analysis: 1, 2, 3, 4, 5, 6, 7, 8
- cell type and respiratory epithelial cell: 1, 2, 3, 4, 5, 6, 7, 8
- cell type and respiratory tract: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41
Co phrase search for related documents, hyperlinks ordered by date